sars-cov-2 donor-recipient immunity transfer

Conditions: Accelerated Phase CML, BCR-ABL1 Positive; Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia; Chronic Lymphocytic Leukemia; Chronic Phase CML, BCR-ABL1 Positive; COVID-19 Infection; Hematopoietic and Lymphoid Cell Neoplasm; Hodgkin Lymphoma; Lymphoblastic Lymphoma; Myelodysplastic Syndrome; Myelofibrosis; Myeloproliferative Neoplasm; Non-Hodgkin Lymphoma

Summary: this study investigates whether donors with previous exposure to covid-19 can pass their immunity by hematopoietic (blood) stem cell transplant (hct) donation to patients that have not been exposed. severe acute respiratory syndrome coronavirus 2 (sars-cov-2) is the virus that causes the covid19 infection. this study may provide critical information for medical decision-making and possible immunotherapy interventions in immunocompromised transplant recipients, who are at high risk for covid19 severe illness.

primary objective: i. to establish the possibility of anti-sars-cov-2 adaptive immunity transfer from matched related (mrd) or unrelated (mud) hct donor to hct recipient. secondary objectives: i. to explore anti-sars-cov-2 adaptive immunity transfer in the haploidentical (haplo) hct setting. ii. to assess the prevalence and change over time of sars-cov-2 seropositive donors among all consented donors. outline: donors: prior to hct, sibling donors (mrd and haplo) undergo a nasopharyngeal swab per standard of care for sars-cov-2 testing. for mud donors, initial testing may consist of a questionnaire. all donors undergo collection of blood and saliva at the time of granulocyte-colony stimulating factor (g-csf). donors' medical charts are also reviewed. recipients: patients undergo a nasopharyngeal swab for sars-cov-2 testing at 30, 60, 90, 120 days post-hct, and afterwards as deemed necessary by the treating physician. patients also undergo the collection of blood and saliva specimens at days 30, 60, 90, 120, 150, and 180 post-hct. recipients' medical charts are also reviewed.

Eligibility criteria:
inclusion criteria: * all cohorts: documented written informed consent of the participant * all cohorts: recipients must have a planned allogeneic hct procedure. mrd, mud, and haplo hct allowed. usage of post-transplant cyclophosphamide (ptcy) permitted only in haplo setting * all cohorts: gcsf-mobilized peripheral blood stem cell (pbsc) only as graft source * all cohorts: planned hct with minimal to no-t cell depletion of graft for the treatment of the following hematologic malignancies: * lymphoma (hodgkin and non-hodgkin) * myelodysplastic syndrome * acute lymphoblastic leukemia in first or second remission (for acute lymphoblastic leukemia/lymphoblastic lymphoma, the disease status must be in hematologic remission by bone marrow and peripheral blood. persistent lymphadenopathy on computed tomography \[ct\] or ct/positron emission tomography \[pet\] scan without progression is allowed) * acute myeloid leukemia in first or second remission * chronic myelogenous leukemia in first chronic or accelerated phase, or in second chronic phase * other hematologic malignancies including chronic lymphocytic leukemia, myeloproliferative disorders and myelofibrosis * all cohorts: willingness to * provide blood samples and saliva specimens * permit medical record review * additional criteria for recipients in the main cohort: * absence of documented covid-19 history and active covid-19 infection * additional criteria for recipients in the reference cohort: active covid-19 infection during hct